[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100406347":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":25,"responsibleParty":43,"collaborators":7,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","L-MTP-PE","L-MTP-PE will be administered at a dose of 2mg\u002Fm2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.",[14],{"name":15,"affiliation":5,"role":16},"Emily Slotkin, MD","PRINCIPAL_INVESTIGATOR",[18,22],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","212-639-8856","slotkine@mskcc.org",{"name":23,"role":19,"phone":24,"phoneExt":7,"email":7},"Paul Meyers, MD","212-639-5952",[26],{"facility":27,"status":28,"city":29,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","AVAILABLE","New York","10065","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-74.00597,40.71427,{"lat":37,"lon":36},[40,41,42],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":7},{"name":23,"role":19,"phone":24,"phoneExt":7,"email":7},{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":44,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100406347","expanded-access-use-of-l-mtp-pe-for-the-treatment-of-osteosarcoma-100406347",false,"NCT04571229","Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma","Inclusion Criteria:\n\n* Confirmed diagnosis of osteosarcoma of any age Note: Patients with either newly diagnosed or relapsed osteosarcoma are eligible.\n* Surgical resection or other definitive local control therapy of all clinically detectable sites of osteosarcoma\n* L-MTP-PE is deemed to be of potential benefit by the treating investigator\n* Willing and able to understand and sign informed consent and assent as appropriate\n* Life expectancy \\> 6 weeks\n* Adequate organ function as follows:\n* Adequate bone marrow function defined as:\n\n  * absolute neutrophil count (ANC) ≥ 750\u002Fmm\\^3\n  * platelet count ≥ 30,000\u002F mm\\^3\n  * hemoglobin ≥ 8 g\u002Fdl\n* Adequate renal function defined as:\n\n  * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL\u002Fmin\u002F1.73m\\^2 OR\n  * Serum creatinine ≤ 2x the upper limit of normal based on age\u002Fgender\n* Adequate liver function defined as:\n\n  * Bilirubin (sum of conjugated + unconjugated) ≤ 2x upper limit of normal for age or ≤ 4x upper limit of normal if thought to have Gilbert's disease\n  * AST or ALT ≤ 3x upper limit of normal or ≤ 5x upper limit of normal for patients with liver metastases\n* Willing to use a barrier method of contraception throughout the course of the study and for 1 year after participation if relevant\n\nExclusion Criteria:\n\n* Use of chronic steroids of other immunosuppressive agents\n* Pregnant or breast feeding","ALL","EXPANDED_ACCESS","This expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system kill cancer cells.",[55],"Osteosarcoma",[11,57,58],"Expanded Access","20-324","2026-05-08",{"date":61,"type":62},"2026-05-11","ACTUAL",{"name":5,"class":6},1]